Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats

Haybar, H. and Goudarzi, M. and Mehrzadi, S. and Aminzadeh, A. and Khodayar, M.J. and Kalantar, M. and Fatemi, I. (2019) Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats. Biomedicine and Pharmacotherapy, 109. pp. 530-535.


Download (1MB) | Preview
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....


Cardiotoxicity is an adverse effect of the anticancer drug doxorubicin (DOX). Gemfibrozil (GEM) is a lipid-lowering drug with a number of biological properties such as anti-inflammatory and antioxidant activities. Therefore, we decided to investigate the effect of GEM on DOX-induced cardiotoxicity in rats. Twenty-eight adult male Wistar rats were divided into four experimental groups as follows: Group I received normal saline (2 ml/kg) orally for 14 days, group II received DOX (2.5 mg/kg; in six injections; accumulative dose: 15 mg/kg) intraperitonially for 14 days, group III received DOX + GEM (100 mg/kg) orally for 14 days concomitantly with DOX administration, and group IV received GEM orally for 14 days. Lipid panel, various biochemical biomarkers, and histological observations were evaluated in serum and heart samples. According to our results, DOX significantly increased the levels of lipid panel (triglycerides, total cholesterol, and low-density lipoproteins cholesterol) as well as markers of cardiac dysfunction (Aspartate aminotransferase, Creatine kinase-muscle/brain, Lactate dehydrogenase and Cardiac Troponin I). Moreover, DOX significantly increased malondialdehyde and nitric oxide levels in cardiac tissue. Furthermore, administration of DOX reduced the level of glutathione as well as the superoxide dismutase, catalase, and Glutathione peroxidase activities. DOX-treated rats showed significantly higher tumor necrosis factor-α and interleukin-1β. GEM administration significantly attenuated the lipid panel and biochemical biomarkers in DOX-treated rats. Our results were confirmed by histopathological evaluations of the heart. Based on our findings, GEM is a promising cardioprotective agent in patients treated with DOX through mitigative effects on biochemical markers and oxidative stress indices. © 2018 Elsevier Masson SAS

Item Type: Article
Additional Information: cited By 0
Subjects: WG Cardiovascular System
Depositing User: eprints admin
Date Deposited: 13 Oct 2020 04:58
Last Modified: 13 Oct 2020 04:58
URI: http://eprints.iums.ac.ir/id/eprint/15480

Actions (login required)

View Item View Item